Surveillance of Invasive Mold Infections in Patients Following Lung Transplantation: Effect of Antimycotic Prophylaxis with Itraconazol and Voriconazole

FRAUKE MATTNER, MD, STEFAN FISCHER, MD, MS, HARTMUT WEISSBRODT, MD, BERND HAUBITZ, MD, JENS GOTTLIEB, MD, IRIS F. CHABERNY, MD, ANDRE SIMON, MD, PETRA GASTMEIER, MD, MARTIN STRU¨ BER, MD;

Author address: 

University of Medicine, Hannover, Germany.

Abstract: 

Background: Pharmacological prophylaxis in immunosuppressed patients aim for the reduction of mortality and morbidity of invasive aspergillosis (IA). Methods: Between Jan 2002 and June 2005 all 295 patients (pts) that underwent lung transplantation (LTx) at our institution were prospectively surveyed. Diagnosis of IA was performed according to the EORTC criteria. Only "œprobable" and "œproven" cases were considered. Usually itraconazol is administered as antimycotic prophylaxis from the day of transplantation onwards. For a high-risk subgroup voriconazol was administered for 4 weeks. Results: In total, 12 out of the 295 pts developed "œprobable" or "œproven" IA (4.0%) within 17±15 days after LTx. This was associated with a 3 fold increased mortality compared to all pts without aspergillosis (p
2006

abstract No: 

550

Full conference title: 

Infectious Diseases Society of America, 44th Annual Meeting
    • IDSA 44th